ArticleNeurourology and urodynamics2026
Urinary Cytokines in Predicting Intradetrusor Onabotulinumtoxin-A Response.
Article in Neurourology and urodynamics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reevaluating predictive factors for treatment success in therapy with OnabotulinumtoxinA for iOAB in a real-world study.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThe impact of asymptomatic bacteriuria and inflammation on response to Onabotulinumtoxin-A for overactive bladder is poorly understood. This work compares baseline differences in asymptomatic bacteriuria status and urinary inflammatory markers between women who respond to Onabotulinumtoxin-A and those who do not. MATERIALS AND
methodsWomen undergoing intradetrusor Onabotulinumtoxin-A injection for refractory overactive bladder submitted a catheterized urine sample to assess for asymptomatic bacteriuria and quantification of 12 urinary cytokines and chemokines at the time of injection. Clinical responders were defined as meeting a minimal clinical difference of > 11 on the Urinary Distress Inventory Short Form after treatment. The proportion of asymptomatic bacteriuria and concentration of urinary biomarkers in Onabotulinumtoxin-A responders compared to non-responders were analyzed.
resultsOf the 75 participants, 45 (60%) were Onabotulinumtoxin-A responders. Responders did not differ in baseline characteristics apart from age (66.0 ± 14.2 [responders] vs. 74.3 ± 7.8 years [non-responders], p < 0.01). There was no difference in asymptomatic bacteriuria rates in responders (37.8%) versus non-responders (40.7%, p = 0.09). No single inflammatory marker was predictive of treatment response when controlling for age. Decision tree analysis allowed for 80% classification accuracy of responders. MCP1 and IP10 were major features in the decision tree analysis, but their impact varied by age. Adding asymptomatic bacteriuria to the decision tree analysis did not improve classification nor function as an important predictive feature.
conclusionsAsymptomatic bacteriuria does not affect Onabotulinumtoxin-A response. Older women were less likely to respond to Onabotulinumtoxin-A treatment and experienced a differential impact of inflammatory cytokines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.